Home › Companies › ITEOS THERAPEUTICS INC. › 2023-2024
At ITEOS THERAPEUTICS INC.'s shareholder meeting held June 11, 2024, in the 2023-2024 proxy season, 55 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 492 separate fund positions. On the most widely held item on that ballot — Election of the Class I director nominees to serve until the 2027 Annual Meeting of… — ITEOS THERAPEUTICS INC.'s filing reports the nominee as elected, with 99.2% support of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ITEOS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ITEOS THERAPEUTICS INC.’s Form 8-K, filed June 13, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 11, 2024: 3 items on ITEOS THERAPEUTICS INC.’s Form 8-K, filed June 13, 2024: 2 elected · 1 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore ITEOS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ITEOS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jill M. DeSimone | 28,724,939 | -- | -- | 54,593 | 2,826,708 | 99.8% | Elected | — |
| Elect Director: David K. Lee | 28,569,456 | -- | -- | 210,076 | 2,826,708 | 99.2% | Elected | — |
| Company's stockholders approved the ratification of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public account firm. | 31,530,823 | 62,078 | 13,339 | -- | 0 | 99.8% | Approved | — |
Source: ITEOS THERAPEUTICS INC., Form 8-K, filed with the SEC on June 13, 2024 — read the filing on EDGAR.
Each item below shows how the 55 asset managers that disclosed a ITEOS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I director nominees to serve until the 2027 Annual Meeting of Stockholders: David K. Lee
ITEOS THERAPEUTICS INC.’s own tally for this item (“Elect Director: David K. Lee”): 28,569,456 for, 210,076 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The final voting results for the Annual Meeting are as follows: The Company's stockholders elected each of the Class I director nominees.”
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 6,253,722 for, 87,367 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,717,049 | 0 | 0 | 0 | For |
| Vanguard | 1,466,634 | 0 | 0 | 0 | For |
| Dimensional | 661,205 | 0 | 0 | 0 | For |
| Fidelity | 612,124 | 0 | 0 | 0 | For |
| TIAA | 370,600 | 0 | 0 | 0 | For |
| Charles Schwab | 206,060 | 0 | 0 | 0 | For |
| Goldman Sachs | 195,257 | 0 | 0 | 0 | For |
| Nationwide | 102,053 | 0 | 0 | 0 | For |
| Victory Capital | 93,760 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 78,294 | Withhold |
| Columbia Threadneedle | 77,454 | 0 | 0 | 0 | For |
| Invesco | 75,658 | 0 | 0 | 0 | For |
| Equitable | 74,313 | 0 | 0 | 0 | For |
| EA Series Trust | 58,517 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,838 | 0 | 0 | 0 | For |
| Prudential/PGIM | 47,650 | 0 | 0 | 0 | For |
| SEI | 40,884 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 38,901 | 0 | 0 | 0 | For |
| American Century | 37,424 | 0 | 0 | 0 | For |
| WisdomTree | 33,251 | 0 | 0 | 0 | For |
| ETF Series Solutions | 26,750 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 25,088 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 23,900 | 0 | 0 | 0 | For |
| GuideStone | 21,349 | 0 | 0 | 0 | For |
| Voya | 20,107 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I director nominees to serve until the 2027 Annual Meeting of Stockholders: Jill M. DeSimone
ITEOS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jill M. DeSimone”): 28,724,939 for, 54,593 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The final voting results for the Annual Meeting are as follows: The Company's stockholders elected each of the Class I director nominees.”
Support: 99.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 6,332,016 for, 9,073 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,717,049 | 0 | 0 | 0 | For |
| Vanguard | 1,466,634 | 0 | 0 | 0 | For |
| Dimensional | 661,205 | 0 | 0 | 0 | For |
| Fidelity | 612,124 | 0 | 0 | 0 | For |
| TIAA | 370,600 | 0 | 0 | 0 | For |
| Charles Schwab | 206,060 | 0 | 0 | 0 | For |
| Goldman Sachs | 195,257 | 0 | 0 | 0 | For |
| Nationwide | 102,053 | 0 | 0 | 0 | For |
| Victory Capital | 93,760 | 0 | 0 | 0 | For |
| MFS | 78,294 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 77,454 | 0 | 0 | 0 | For |
| Invesco | 75,658 | 0 | 0 | 0 | For |
| Equitable | 74,313 | 0 | 0 | 0 | For |
| EA Series Trust | 58,517 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,838 | 0 | 0 | 0 | For |
| Prudential/PGIM | 47,650 | 0 | 0 | 0 | For |
| SEI | 40,884 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 38,901 | 0 | 0 | 0 | For |
| American Century | 37,424 | 0 | 0 | 0 | For |
| WisdomTree | 33,251 | 0 | 0 | 0 | For |
| ETF Series Solutions | 26,750 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 25,088 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 23,900 | 0 | 0 | 0 | For |
| GuideStone | 21,349 | 0 | 0 | 0 | For |
| Voya | 20,107 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE BEDRIJFSREVISOREN / REVISEURS D'ENTREPRISES BV/SRL AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
ITEOS THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved the ratification of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public account firm.”): 31,530,823 for, 62,078 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the ratification of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public account firm.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 6,273,499 for, 58,517 against, 9,073 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,717,049 | 0 | 0 | 0 | For |
| Vanguard | 1,466,634 | 0 | 0 | 0 | For |
| Dimensional | 661,205 | 0 | 0 | 0 | For |
| Fidelity | 612,124 | 0 | 0 | 0 | For |
| TIAA | 370,600 | 0 | 0 | 0 | For |
| Charles Schwab | 206,060 | 0 | 0 | 0 | For |
| Goldman Sachs | 195,257 | 0 | 0 | 0 | For |
| Nationwide | 102,053 | 0 | 0 | 0 | For |
| Victory Capital | 93,760 | 0 | 0 | 0 | For |
| MFS | 78,294 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 77,454 | 0 | 0 | 0 | For |
| Invesco | 75,658 | 0 | 0 | 0 | For |
| Equitable | 74,313 | 0 | 0 | 0 | For |
| EA Series Trust | 0 | 58,517 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 47,838 | 0 | 0 | 0 | For |
| Prudential/PGIM | 47,650 | 0 | 0 | 0 | For |
| SEI | 40,884 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 38,901 | 0 | 0 | 0 | For |
| American Century | 37,424 | 0 | 0 | 0 | For |
| WisdomTree | 33,251 | 0 | 0 | 0 | For |
| ETF Series Solutions | 26,750 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 25,088 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 23,900 | 0 | 0 | 0 | For |
| GuideStone | 21,349 | 0 | 0 | 0 | For |
| Voya | 20,107 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 38,273,795 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 4.49% |
| 2 | Vanguard | 3.83% |
| 3 | Dimensional | 1.73% |
| 4 | Fidelity | 1.60% |
| 5 | TIAA | 0.97% |
| 6 | Charles Schwab | 0.54% |
| 7 | Goldman Sachs | 0.51% |
| 8 | Nationwide | 0.27% |
| 9 | Victory Capital | 0.24% |
| 10 | MFS | 0.20% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| EcoR1 Capital, LLC | 27.93% | 13D |
| TANG CAPITAL MANAGEMENT, LLC | 10.00% | 13D |
| BVF PARTNERS L P/IL | 8.03% | 13G |
| BlackRock Portfolio Management LLC | 6.09% | 13G |
| BlackRock, Inc. | 5.69% | 13G |
| RA Capital Management, L.P. | 5.58% | 13D |
| ANSBERT GADICKE | 4.71% | 13D |
| The Vanguard Group | 3.90% | 13G |
| Ridgeback Capital Investments L.P. | 3.77% | 13G |
| Citadel Advisors | 3.17% | 13F |
Percentages above are of 38,273,795 shares outstanding, as reported by ITEOS THERAPEUTICS INC. on its Form 10-Q dated April 22, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ITEOS THERAPEUTICS INC.’s 10-Q dated April 22, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ITEOS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.
proxyvotesnow.com, “ITEOS THERAPEUTICS INC. 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/iteos-therapeutics-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.